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Summary objectives To report immunovirological outcomes and resistance patterns in adults treated with triple
combination antiretroviral therapy (cART) for 4 years in an HIV programme of Phnom Penh,
Cambodia.
methods It is a longitudinal study and cross-sectional evaluation of adults receiving cART for 4 years.
CD4 cell counts and HIV-1 RNA were quantiﬁed, and resistance patterns were determined. Drug-related
toxicity was assessed by clinicians and through laboratory testing.
results After 4 years of cART start, the cumulative probability of retention in care was 0.80 and
survival among patients not lost to follow-up was 0.85. A total of 349 patients (98% of eligible)
participated in the cross-sectional evaluation. Ninety per cent were receiving ﬁrst-line therapy, 29%
stavudine- and 58% zidovudine-containing regimens (compared with 94% and 3% at cART initiation).
Ninety-three per cent of patients were clinically asymptomatic, and severe lipodystrophy and dyslipi-
demia were diagnosed in 7.2% and 4.0%, respectively. Good treatment adherence was reported by 83%
of patients. Median CD4 T-cell count was 410 cells⁄ll [IQR 290–511], and 90% of patients had >200
cells⁄ll. Only 15 (4%) patients had detectable HIV viral load (eight had <200 CD4 cells⁄ll), ﬁve had
thymidine analogue mutations, and nine were resistant to two drug classes. In an intention-to-treat
analysis, 26.1% (95% CI 22.0–30.5) of patients had failed ﬁrst-line therapy.
conclusions In this Cambodian cohort of adults who started cART at an advanced stage of HIV
disease, we observed good clinical and immunovirological outcomes and self-reported treatment
adherence at 4 years of therapy.
keywords HIV, programme evaluation, treatment failure, drug resistance, developing countries
Introduction
The provision and scale-up of HIV⁄AIDS treatment in
resource-limited countries has been possible through a
public health approach consisting of a limited biological
follow-up, strengthening of adherence and use of generic,
ﬁxed-dose combinations (FDC) of antiretroviral (ARV)
drugs. Recent evaluations of clinico-immunological out-
comes of patients using this approach have shown the
feasibility and effectiveness of triple combination ARV
therapy (cART) provided to patients treated in these
settings (Walsh et al. 2002; Orrell et al. 2003; World
Health Organization, 2006; Ferradini et al. 2007). Regular
evaluations of immunovirological response, tolerability,
and patient adherence to therapy in clinical practice are
scarce but necessary to determine the long-term effective-
ness of programmes. They are also essential to optimize
strategies of care that maximize the duration of ﬁrst-line
cART.
In 2001, Me ´decins Sans Frontie `res (MSF), in collabora-
tion with the Cambodian Ministry of Health, started
providing free cART to HIV-infected patients at the Khmer
Soviet Friendship Hospital of Phnom Penh, Cambodia. We
reported previously the favourable immunovirological
results of adults treated with cART for 2 years in this
programme (Ferradini et al. 2007). The objective of this
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comes and ARV-related adverse events diagnosed in
patients receiving cART for 4 years.
Methods
HIV programme of Phnom Penh
HIV-infected patients treated in the HIV programme of
Phnom Penh attend regular clinic visits by physicians and
receive intensive counselling and education support by
experienced counsellors before (at least two pre-ART
individual sessions) and after cART start (every month
during the ﬁrst 4 months and every 6 months thereafter).
Patient immunological monitoring is performed every
6 months, but routine virological testing is not available.
First-line therapy provided in the programme is a ﬁxed-
dose combination of two nucleoside reverse transcriptase
drugs (NRTI), generally stavudine (d4T) and lamivudine
(3TC) and one non-NRTI (NNRTI), nevirapine (NVP) or
efavirenz (EFV). Alternative ﬁrst-line regimens are avail-
able in case of occurrence of side effects [e.g. d4T could be
replaced by zidovudine (AZT), and AZT could be replaced
by tenofovir (TDF)]. Second-line therapy containing
boosted lopinavir (LPV⁄r) and didanosine (ddI) and one or
two additional NRTI drugs was provided, when treatment
failure was diagnosed (WHO 2003 criteria).
Tuberculosis diagnosis is based on the results of micro-
scopic examination of body specimens (e.g. sputum,
pleural effusion, cerebrospinal ﬂuid) for acid-fast bacilli,
and⁄or radiological ﬁndings suggestive of active pulmo-
nary tuberculosis performed in patients with clinical
suspicion of the disease. To differentiate between tuber-
culosis and non-tuberculosis mycobacteria, since 2006,
culture is systematically performed for suspected tubercu-
losis cases with negative direct examination results.
Study population and procedures
Adults aged 18 years or older, excluding pregnant
women, who started treatment between October 2002
and June 2003 (48 ± 2 months before the study inclusion
period) in the MSF-supported HIV programme in Phnom
Penh and still receiving treatment were invited to
participate in a cross-sectional survey. After obtaining
written informed consent, information on patients’ age,
sex, body mass index (BMI) and treatment history was
collected. Additionally, data on the presence of ARV-
related adverse events in the previous 30 days were
collected by physicians using standardized questionnaires.
Patients were asked whether they experienced speciﬁc
symptoms from a pre-deﬁned list and whether these
interfered with normal activity. Adverse events were
graded according to WHO guidelines (World Health
Organization, 2006).
During the study visit, non-medical counsellors assessed
compliance with cART using a 10-point visual analogue
scale (VAS) to assess self-reported adherence over the
previous month (Walsh et al. 2002). Patients were asked to
rate themselves concerning the amount of ARV medication
taken during the previous month (0 = no medication taken;
10 = all medication taken). They were classiﬁed as fully
adherent if they had a VAS of 10 (all pills taken as
prescribed) and poorly adherent if they had a VAS <10.
Laboratory testing
Blood specimens were collected from fasting patients, and
concentrations of haemoglobin, creatinine, transaminases,
alkaline phosphatases, glucose, triglycerides and both total
and low high-density lipoprotein (HDL) cholesterol were
measured. The number of blood platelets and neutrophils
was also determined. Plasma HIV-1 RNA viral load was
quantiﬁed with real-time polymerase chain reaction (G2
generic HIV viral load ANRS kit, Biocentric, Bandol,
France; limit of detection, 250 copies⁄ml) at the Pasteur
Institute of Phnom Penh. HIV genotyping was performed
for patients with virological failure (viral load>1000 cop-
ies⁄ml), reverse transcriptase genotyping was performed
for all patients, and protease genotyping additionally for
those receiving second-line therapy. To do this, HIV RNA
was extracted from plasma using standard methods
developed by the Agence Nationale de Recherche sur le
SIDA et les He ´patites Virales (ANRS) French Resistance
Study Group (http://www.hivfrenchresistance.org/tab
2007.html). Phylogenetic analysis was performed in both
reverse transcriptase (RT) and protease (PR) genes. PCR
ampliﬁed fragments were sent to the Macrogen Company
(Macrogen Inc., Seoul, Korea). Chromatograms sent back
electronically to the Pasteur Institute of Cambodia were
veriﬁed, analysed and interpreted. Clustal X 1.81 software
was used for alignment with subtype reference sequences set
from the Los Alamos HIV sequence Database (http://hiv
web.lanl.gov/content/HIVdb/SUBTYPE_REF/align.htlm)
as well as for phylogenetic analysis using a nucleotide-
distance matrix and the bootstrap neighbour-joining
method. The resistant mutations were deﬁned according
to the WHO HIV Drug resistance database (http://
hivdb.stanford.edu/pages/WHOResistanceList.html), and
the drug susceptibility was predicted according to the
ANRS algorithm (http://www.hivfrenchresistance.org/).
CD4 T-cell counts were measured by ﬂow cytometry
(FACScount; Becton Dickinson, Franklin Lakes, NJ,
USA).
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Data were double-entered in EpiData 3.1 (Odense,
Denmark), and analyses performed in Stata 9.0 (Stata
Corp., College Station, TX, USA). Patient information was
right-censored at death, last visit for lost to follow-up,
transfer to another programme or at 48 months for other
patients. Patients lost to follow-up were those who had
missed their last clinical appointment by 2 months or
more. Kaplan–Meier methods were applied to estimate
probabilities of survival and retention in care. CD4 cell
counts were categorized as follows: <50, 50–199, 200–499,
‡500 cells⁄ll. Chemistry laboratory values were classiﬁed
into severity grades according to recommended WHO
grading schemes (World Health Organization, 2006).
Absolute and CD4 cell gains by initial CD4 cell level were
compared with Wilcoxon rank-sum tests. Differences in
adherence, toxicity and virological failure status in men
and women, and differences in adherence in patients with
and without detectable viral load were tested with chi-
square or Fisher’s exact tests, as appropriate. Coefﬁcient
correlations between adherence and virological failure
status were calculated. Finally, an intention-to-treat anal-
ysis was performed to estimate the rate of virological
failure to ﬁrst-line therapy within the subgroup of patients
who survived 3 months of cART, assuming that all deaths
and lost to follow-up patients had experienced treatment
failure.
The study was approved by the National Ethics Com-
mittee of Cambodia and the Consultative Committee for
People involved in Biochemical Research (CPPRB) of Saint
Germain-en-Laye, Paris, France.
Results
A total of 467 adults had started cART in the MSF-
supported HIV⁄AIDS programme of Phnom Penh between
24 October 2002 and 23 June 2003. Since the start of
therapy, 63 (14%) patients had died, 29 (6%) had been
lost to follow-up, and 14 (3%) had been transferred to
other health facilities (Figure 1). The cumulative proba-
bility of retention in care at 4 years of cART was 0.80
(95% CI 0.76–0.84), and cumulative survival among those
not lost to follow-up was 0.85 (95% CI 0.82–0.88). At the
time of the study, four women were pregnant, and eight
patients attended the clinic before 46 or after 50 months of
cART start (one of the eight had detectable viral load) and
were therefore not eligible for inclusion in the cross-
sectional survey. A total of 349 patients (98% of those
eligible) participated in the evaluation.
At cART start, patient median age was 34 years, 94%
were ARV naı ¨ve, and 24% had been diagnosed with
tuberculosis (Table 1). Ninety-seven per cent of patients
received d4T-containing therapy, and the majority started
treatment at an advanced stage of HIV disease (59% in
stage 4 and 70% had a CD4 count <50 cells⁄ll).
Patients starting cART in October 2002 – June 2003 
n = 467 (100%) 
Survey participants 
n = 349 (74.7%) 
Deaths n = 63 (14%) 
Loss to follow-up  n = 29 (6%) 
Transfer        n = 14 (3%) 
Excluded (outside study window) 
n = 8 (1.7%) 
Excluded (pregnant) 
n = 4 (0.8%) 
Patients eligible for survey 
n = 357 (76.4%) 
Figure 1 Study ﬂowchart, Phnom Penh,
Cambodia.
Tropical Medicine and International Health volume 16 no 2 pp 205–213 february 2011
M. Pujades-Rodrı ´guez et al. Outcome and resistance after 4 years of ART in Cambodia
ª 2010 Blackwell Publishing Ltd 207Clinico-immunological outcomes
At 4 years of cART, 93% of patients were asymptomatic
(WHO classiﬁcation), and 267 (76%) had BMI of
‡18.5 kg⁄m
2 (1% had BMI <16). Ninety per cent of
patients were receiving ﬁrst-line therapy, 29% d4T- and
58% AZT-containing regimens, and 36 (10%) had been
switched to LPV⁄r-containing second-line therapy because
of treatment failure. Overall, 29.5% of individuals had
reached CD4 T-cell values ‡500 cells⁄ll, 63.2% of these
had initial CD4 counts <50 and 35.8% 50–200. Never-
theless, 35 (10.0%) patients had CD4 T-cell counts
<200 cells⁄ll, and 3 (0.9%) <100 cells⁄ll. Median CD4
increases were 101 [IQR 64–141; n = 309] at 6 months,
151 [96–213; n = 312] at 1 year, 245 (159–336; n = 308)
at 2 years and 356 cells⁄ll [263–474; n = 324] at 4 years
of cART. Median CD4 gains were higher in patients with
lower initial CD4 cell counts, but higher median values
were observed in individuals with higher initial CD4
measurements (P = 0.002 for both comparisons; Figure 2).
Patients with <50 CD4 cell counts⁄ll at ART start had a
median count of 392 cells⁄ll [IQR 280–506] and median
gain of 380 [IQR 271–495], and those with ‡100 cells⁄ll
had median 473 [411–570] and 321 [IQR 263–427],
respectively. A total of 109 (31.2%) patients reached
their highest CD4 T-cell values after 4 years of cART
use.
ARV-related adverse events and laboratory abnormalities
Most individuals (80%) reported clinical adverse events,
namely morphological disorders (63%), asthenia (32%),
peripheral neuropathy (25%) and digestive symptoms
(21%). These were mostly of mild to moderate severity.
Intolerance of grade 3 was diagnosed in 31 (9%) patients;
no grade 4 clinical toxicity was recorded (Table 1). One
patient with severe neuropathy was receiving TDF-con-
taining therapy but had previously been treated with d4T
for 17 months and with AZT for 23 months. Grade 3
morphological disorders were diagnosed in 25 patients
who had taken d4T for a median of 29 months; six of them
were still receiving d4T-containing therapy at the time of
the survey.
Eighty-ﬁve per cent had at least one abnormal laboratory
measurement, speciﬁcally dyslipidemia (73%) and in-
creased liver enzymes (27%). Only 1% had anaemia. Of
the 26 patients with mild to moderate high creatinine levels
(16% of patients on second line and 6% of those on ﬁrst
line), only three were receiving TDF-containing therapy for
a median of 14 months; six were receiving boosted LPV-
containing regimens; and 17 a combination of 3TC with
d4T or AZT, and EFV or NVP. Grade 3 or 4 laboratory
abnormalities were observed in 36 (10%) patients. Four of
the 24 patients with severe hypertriglyceridemia were
receiving second-line regimens (11% compared to 6% of
individuals on ﬁrst line), and one of the three patients with
Table 1 Patient characteristics at antiretroviral therapy start and
at 4 years of therapy use, Phnom Penh, Cambodia
Study
participants
(N = 349)
Characteristics at cART start
Men (%) 137 (60.5)
Median age, years [IQR] 34 [31–39]
ART naive (%) 328 (94.0)
d4T-3TC-EFV regimen (%) 287 (82.7)
WHO stage 4 (%) 207 (59.3)
Body mass index <18.5, kg⁄m
2 (%) 143 (43.9)
Median CD4 T-cell count,
cells⁄ll
3 [IQR]
16 [4–71], n = 324
Characteristics at survey
Non-cumulative WHO stage at survey (%)
Asymptomatic 326 (93.4)
Stage 3 or 4 8 (2.2)
Median body mass index, kg⁄m
2 [IQR] 20 [19–23]
Second-line LPV-based therapy (%) 36 (10.3)
Severe reported clinical ARV toxicity (%) Grade 3 Grade 4
Digestive disorders 1 (0.3) –
Neurological disorders 1 (0.3) –
Dermatological disorders 1 (0.3) –
Lipodystrophy 25 (7.2) –
Severe laboratory-based ARV toxicity (%) Grade 3 Grade 4
Haematological disorders 2 (0.6) 2 (0.6)
High ALT or AST 4 (1.2) –
Hypertriglyceridemia 14 (4.0) 10 (2.9)
High total cholesterol 2 (0.6) –
Reported adherence over the last month (%)*
Fully adherent 289 (83.3)
Poorly adherent 12 (3.4)
CD4 cell count, cells⁄ll [IQR]
Median 410 [290–511]
Median gain since ART start +354 [262–474]
HIV-1 RNA <250 copies⁄ml (%) 334 (95.7)
3TC, lamivudine; ALT, alanine transferase; AST, aspartate trans-
aminase; ARV, antiretroviral; cART, combined antiretroviral
therapy; d4T, stavudine; IQR, interquartile range; LPV, lopinavir;
NVP, nevirapine. Limits for toxicity of grade 3 were the following:
for haematological disorders: anaemia 6.5–6.9 g⁄dl, hyperleuco-
cytosis 1000–1500⁄mm
3, neutrophilia 500–749⁄mm
3, and
thrombocytosis 20 000–49 999⁄mm
3; for AST and ALT >5–10 ·
upper normal range limit; for total hypercholesterolaemia 10.34–
12.92 mm. mmol/l.
*Self-reported adherence during the past month using a 10-point
visual analogue scale was missing for one patient.
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Virological failure and drug-resistant viruses
Fifteen individuals (4%) had detectable HIV-1 RNA, and
all of these had a viral load of >1000 copies⁄ml (median
4.9 log10; IQR = 3.7–5.3) 4 years after cART start. Three
were receiving second-line therapy for a median of
20 months. Only one patient with virological failure had
CD4 cell count <100, and eight had <200 cells⁄ll. In an
intention-to-treat analysis, 26.1% (95% CI 22.0–30.5) of
cohort members had failed ﬁrst-line cART after 4 years of
use (114⁄437).
Genotyping reactions for two patients with detectable
viral load (one on ﬁrst-line and one on second-line
treatment) failed. The CRF01AE HIV-1 subtype was
isolated in all specimens genotyped. One patient treated
with ﬁrst-line and one with second-line therapy had wild-
type viruses (Table 2). The most frequently observed
mutations were M184V and K103N (nine and ﬁve
patients, respectively). Five patients had thymidine ana-
logue mutations (TAMs): one had TAMs of types 1 and
2; three TAMs of type 1 only, and one TAMs of type 2
only. Eleven individuals had mutations conferring ARV
resistance to NRTIs and⁄or NNRTIs (Figure 3). Eight of
these patients were ARV naı ¨ve at cART start, and 10
were receiving a drug related to the observed drug
resistance at the time of the survey. Nine individuals had
resistance to two drug classes (NRTI and NNRTI). Only
one of the patients who were receiving second-line
therapy had developed mutations but not resistance to
protease after 5.7 months of second-line use. The overall
frequency of cART resistance in the cohort was 2.6%
(9⁄347).
Treatment adherence
After 4 years of cART, 83.3% of patients were considered
fully adherent to cART, and 3.4% poorly adherent
(Table 1). Sixteen per cent of patients with virological
suppression reported suboptimal adherence compared to
40.0% of patients with detectable viral load (Fisher’s exact
P = 0.03). Mean difference in reported adherence between
patients with detectable and undetectable viral load was
0.4% (Wilcoxon rank-sum P = 0.01). The two individuals
with wild-type virus and four of the 11 patients identiﬁed
with resistance reported poor adherence to cART. No
difference in adherence was reported by men and women
(Wilcoxon rank-sum P = 0.17).
Discussion
In this cohort of adults who started cART at an advanced
stage of disease in Phnom Penh, 80% of patients were alive
and receiving care after 4 years of therapy. Most patients
were asymptomatic, received ﬁrst-line regimens, were
compliant with treatment and experienced sustained CD4
cell response to therapy. Only 4% of patients had
detectable HIV viral load, and 10% were at the risk of
developing opportunistic infections (CD4 cell count
<200 cells⁄ll).
Despite late presentation of patients at programme
entry and cART start (68% had CD4 cell count levels <50
cells⁄ll), after 4 years of therapy, 80% of patients
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Figure 2 Immunological response at 4 years of therapy use,
Phnom Penh, Cambodia. (a) Distribution of CD4 cell count
measurements by initial CD4 cell value. (b) Distribution of CD4
cell gains by initial CD4 cell value. Horizontal lines are medians
and interquartile ranges (25th and 75th percentiles); whiskers’
ends represent 5th and 95th percentiles, and dark dots outlier
values.
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encing CD4 cell count gains similar to or higher than
those described in the literature (Garcia et al. 2004), even
in studies conducted among patients who maintained viral
load suppression for several years (Mocroft et al. 2007;
Kelley et al. 2009). Furthermore, almost one-third of the
patients had reached 500 CD4 cells⁄ll at 4 years of
treatment, and greater CD4 count increases were ob-
served in patients with lower initial CD4 counts. These
ﬁndings are also consistent with previous studies (Ya-
mashita et al. 2001; Garcia et al. 2004; Egger et al. 2009;
Kelley et al. 2009). Given that both advanced clinical
disease and low pre-therapy CD4 count levels have been
identiﬁed as important determinants of poor immuno-
logical response and maximum CD4 values achieved on
therapy (Hunt et al. 2003; Etard et al. 2006; Mocroft
et al. 2007; Bussmann et al. 2008; Nash et al. 2008),
earlier start of treatment could further improve long-term
patient outcomes in our programme. Besides the observed
favourable immunological outcomes, which are consistent
with sustained viral load responses over time (Mocroft
et al. 2007; Egger et al. 2009), only 4% of the patients
who remained in care after 4 years of cART (or 26% of
the cohort in the intention-to-treat analysis) failed to
Table 2 Frequency of HIV-1 reverse transcriptase mutations at 4 years of antiretroviral therapy use among patients with HIV-1 RNA
>1000 copies⁄ml, Phnom Penh, Cambodia
Patient
Drug regimens used
since cART start
Mutations Resistance
NNRTI NRTI NNRTI NRTI Protease
First-line therapy
1 AZT-3TC-EFV,
AZT-TDF-LPVr*
– F116FY,
Q151LM
No Yes NA
2 d4T-3TC-NVP Y181C D67N, K70KR,
M184V
Yes Yes NA
3 d4T-3TC-EFV,
AZT-3TC-NVP
Y181C T69N, M184V,
T215Y
Yes Yes NA
4 d4T-3TC-EFV,
AZT-3TC-EFV,
ddI-AZT-EFV
– – No No NA
5 d4T-3TC-EFV,
AZT-3TC-EFV
K103N, P225H M184V Yes Yes NA
6 d4T-3TC-EFV,
AZT-3TC-NVP
K103N, Y181C M184V Yes Yes NA
7 AZT-3TC-EFV,
AZT-3TC-NVP
K101E, G190A M184V, T215F Yes Yes NA
8 AZT-3TC-EFV* K103N, M230L M41L, M184V,
D67N, T69D,
L74V, M184V,
L210W, T215Y
Yes Yes NA
9 d4T-3TC-EFV* L100I, K103N K70R, M184V,
T215I, K219E
Yes Yes NA
10 d4T-3TC-EFV K103N K65R M184V Yes Yes NA
11 AZT-3TC-NVP K103KN M184V Yes Yes NA
Second-line therapy
12 d4T-3TC-EFV,
AZT-3TC-NVP,
ddI-ABC-LPVr
Y181C – Yes No No
13 d4T-3TC-EFV,
AZT-3TC-LPVr
– – No No No
3TC, lamivudine; ABC, abacavir; AZT, zidovudine; cART, combined antiretroviral therapy; d4T, stavudine; ddI, didanosine; EFV,
efavirenz; LPVr, boosted lopinavir; NA, not applicable; NNRTI, non-nucleoside reverse transcriptase inhibitor; NRTI, nucleoside reverse
transcriptase inhibitor; NVP, nevirapine.
*Antiretroviral experienced at therapy start.
Patient number 12 had no protease mutations. Patient number 13 had the following mutations not conferring resistance to protease
inhibitor drugs: H69K, I13V, L10I, M36I, V82I.
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the ﬁndings from previous evaluations conducted in
Gaborone, Botswana and Dakar, Senegal (Etard et al.
2006; Bussmann et al. 2008). In the study from Gabo-
rone, Kaplan–Meier estimates of death or virological
failure of 22% at 3 years (n = 327) and 30% at 5 years
(n = 133) were reported. In Senegal, 44% of 97 patients
had unsuppressed viral load after 4 years of cART use.
We did not observe differences in immunovirological
responses in men and women treated in our cohort. This
lack of association has also been reported by a number of
previous studies (Srasuebkul et al. 2007; Egger et al.
2009). However, other researchers found greater immu-
nological recovery in women than in men (Gandhi et al.
2006; Collini et al. 2009). Discrepancies across studies
might be explained by sex-related differences in initial
clinico-immunological characteristics and⁄or in adherence
levels.
It is important to acknowledge that mortality and loss to
follow-up rates before the survey might have led to
overestimate virological suppression and immunological
recovery rates, as some of the deaths or dropouts
(especially those occurring after the ﬁrst 6 months of
therapy) could primarily represent non-compliant patients
and poor respondents to therapy. However, the intention-
to-treat analysis also showed good results with an overall
cumulative failure rate of ﬁrst-line therapy of 26% at
4 years of treatment. Furthermore, participation rates for
the clinical and laboratory components of the study were
very high (98% of eligible patients) minimizing the
possibility of participation biases.
The CRF01_AE strain, responsible for over 95% of
infections in Thailand, Cambodia and Vietnam (Hemelaar
et al. 2006), was isolated in all specimens genotyped. Of
the 13 patients with virological failure and genotyping
data, nine had mutations to two drug classes, and 11 had
drug resistance. The most prevalent resistance patterns
were against NRTIs (3TC⁄FTC or AZT⁄d4T) and⁄or the
two NNRTIs prescribed (EFV⁄NVP). This is consistent
with reports of associations between NNRTI-based ther-
apy and the development of resistance to multiple drug
classes, probably because of the susceptibility to select for
resistant virus to both 3TC and NNRTI (Harrigan et al.
2005; Tam et al. 2008).
The good immunovirological outcomes observed in our
cohort are consistent with the majority of our patients
achieving sustained levels of adherence to therapy over
time. In our programme, FDC combinations of generic
ARV drugs were given to the patients, and a dedicated
team of experienced non-medical counsellors provided
psychosocial and adherence support at the time of clinical
visits. In the study, we assessed self-reported patient
compliance with cART over the past month using the VAS
tool. Despite the high thresholds of adherence used to
classify patient adherence status (100%), more than 80%
of patients were considered compliant with treatment
regardless of the method used. The observed similar
adherence levels reported by men and women has also been
reported by a recent study in Botswana (Bussmann et al.
2008).
Toxicity attributed to ARV use was frequently diagnosed
in our patients, especially dyslipidemia and d4T-related
toxicity. Similar ﬁndings have been reported by researchers
in Thailand and Singapore (Paton et al. 2002; Homsanit
et al. 2007). Dyslipidemia diagnosed in HIV-infected
patients has been associated with an increased risk of
myocardial infarction of 1.2 per year of cART use in
European cohorts (Friis-Moller et al. 2003). Our results
suggest that counselling to reduce alcohol consumption,
regular assessment of patients’ cardiovascular risk and use
of non-pharmacological approaches, such as diet and
exercise, also need to be considered in the long-term
management of patients receiving cART in resource-
limited settings. In our cohort of patients primarily treated
with d4T-based ﬁrst-line therapy, lipodystrophy was
diagnosed in 63% of patients (severe symptoms in 7%),
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Figure 3 Frequency of HIV antiretroviral resistance by drug class
and treatment line at 4 years of therapy use, Phnom Penh, Cam-
bodia. 3TC, lamivudine; ABC, abacavir; AZT, zidovudine; d4T,
stavudine; ddI, didanosine; EFV, efavirenz; FTC, emtricitabine;
NRTI, nucleoside reverse transcriptase inhibitor; NNRTI, non-
nucleoside reverse transcriptase inhibitor; NVP, nevirapine; TDF,
tenofovir.
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of mitochondrial toxicity are known to increase with the
duration of treatment (Carr & Cooper 2000), and several
studies have reported strong associations between presence
of lipodystrophy and d4T use (Hurst & Noble 1999; Saint-
Marc et al. 1999; Carr & Cooper 2000; Fellay et al. 2001).
This condition has also been observed more frequently in
patients with low nadir CD4 count (Mauss et al. 2002). In
clinical practice, physicians might tend to underestimate
the frequency and anxiety associated with the presence of
minor or mild adverse events (Justice et al. 1999). How-
ever, real or anticipated drug side effects have been
identiﬁed as important barriers to treatment adherence in
several studies (Bassetti et al. 1999; Ammassari et al. 2001,
2002; Weiser et al. 2003), and non-life threatening toxic-
ity, even if of minor severity, could lead to suboptimal
adherence to therapy, treatment discontinuation and fail-
ure. As recommended in new WHO guidelines (World
Health Organization, 2010), the use of better tolerated
ﬁrst-line ARV regimens containing TDF or AZT would
help decreasing the development of long-term toxicity in
patients receiving cART. Supportive open discussion and
education of patients to balance beneﬁts and constraints
related to the use of therapy are simple key strategies that
can help to ensure long-term adherence to cART (Mills
et al. 2006).
In conclusion, the results of this study support the
feasibility and long-term effectiveness of the care strategy
adopted by the MSF-supported HIV⁄AIDS programme in
Phnom Penh, which employed a combination of regular
clinical follow-up visits by physicians, regular routine CD4
cell count monitoring, use of cART FDC and the provision
of regular adherence and psychosocial support led by well-
trained counsellors.
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